Experience with weekly doxorubicin (adriamycin) in hormone-refractory stage D2 prostate cancer
References (15)
- et al.
Hormone-refractory metastatic prostatic cancer treated with methotrexate, cyclophosphamide plus Adriamycin, cis-platinum plus 5-fluorouracil plus cyclophosphamide
Urology
(1988) Phase II trial of doxorubicin in bidimensionally measurable prostatic adenocarcinoma
J Urol
(1984)- et al.
Treatment of stage IV carcinoma of the prostate
Urol Clin North Am
(1978) The natural historv of prostate carcinoma
Cancer
(1973)National randomized study of chemotherapeutic agents in advanced prostatic carcinoma: a progress report
Cancer Treat Rep
(1977)A comparative clinical trial of Adriamycin and 5-florouracil in advanced prostatic cancer: prognostic factors and response
Prostate
(1983)- et al.
Low dose methotrexate and doxorubicin in hormone resistant prostatic cancer
Br J Urol
(1990)
Cited by (35)
A new jasmonic acid stereoisomeric derivative induces apoptosis via reactive oxygen species in human prostate cancer cells
2012, Cancer LettersCitation Excerpt :However, in advanced stages of prostate cancer, growth and development typically become refractory to androgen effects and cells continue to grow unchecked [3]. Aggressive treatment of patients with combination chemotherapy usually results in severe side-effects and is rarely curative [4–6]. In fact, androgen-independent tumors also become resistant to a wide variety of cytotoxic drugs.
Effect of vicanicin and protolichesterinic acid on human prostate cancer cells: Role of Hsp70 protein
2012, Chemico-Biological InteractionsCitation Excerpt :However, in advanced stages of prostate cancer, growth and development typically become refractory to androgen effects and cells continue to grow unchecked [24]. Aggressive treatment of patients with combination chemotherapy usually results in severe side-effects and is rarely curative [25–27]. In fact, androgen-independent tumors also become resistant to a wide variety of cytotoxic drugs.
Pro-apoptotic activity of ergosterol peroxide and (22E)-ergosta-7,22-dien-5α-hydroxy-3,6-dione in human prostate cancer cells
2010, Chemico-Biological InteractionsThe role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer
2008, Cancer Treatment ReviewsCitation Excerpt :A phase II study reported substantial palliative effect and acceptable toxicity with weekly Epi combined with medroxyprogesterone acetate (MPA), while a randomized trial described that heart failure was frequently observed in patients receiving this combination regimen.57,58 No significant difference in overall survival was found between patients who received weekly Dox 20 plus prednisone (P) or P alone.28 Since a significant synergistic antitumour effect had been demonstrated in vitro in testosterone-sensitive human prostate carcinoma cell line LNCaP with the combination of Epi and the polysulfonated naphtylurea suramin (S), some investigators tested this combination in HRPC patients.59
Biweekly Doxorubicin/Ketoconazole as Second-Line Treatment in Docetaxel-Resistant, Hormone-Refractory Prostate Cancer
2008, UrologyCitation Excerpt :We observed only 1 case of Grade 2 cardiac toxicity. This low incidence of cardiotoxicity should be mainly attributed to the low median total dose of doxorubicin and is consistent with a previous report of a weekly administration of doxorubicin at 20 mg/m2.8 The high occurrence of nail changes is worth discussing.
Hormone refractory prostate cancer: Management and advances
2006, Cancer Treatment Reviews